Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034

Cardiac Biomarkers Testing Devices Market Summary

Overview:

• The Cardiac Biomarkers Testing Devices market is estimated at USD 5.24 billion in 2025 and is projected to reach USD 11.77 billion by 2034. Growth is anchored in the rising global burden of cardiovascular disease, expanding adoption of high-sensitivity troponin assays, and the growing deployment of point-of-care cardiac testing across emergency and ambulatory care settings.
• The global Cardiac Biomarkers Testing Devices market is growing at a CAGR of 9.4% during the forecast period from 2026 to 2034.
• By product type, the reagents & kits segment dominated the Cardiac Biomarkers Testing Devices market with a 64% share in 2025.
• By biomarker type, the troponin segment dominated the Cardiac Biomarkers Testing Devices market with a 43% share in 2025.
• By testing setting, the laboratory testing segment dominated the Cardiac Biomarkers Testing Devices market with a 68% share in 2025.
• By application, the acute coronary syndrome segment dominated the Cardiac Biomarkers Testing Devices market with a 56% share in 2025.
• By end-user, the hospitals segment dominated the Cardiac Biomarkers Testing Devices market with a 58% share in 2025.
• North America dominated the global Cardiac Biomarkers Testing Devices market revenue with a 39% share in 2025, representing the highest regional market share globally.

Cardiac biomarkers testing devices comprise the instruments, analyzers, reagents, and immunoassay kits used to measure specific proteins and enzymes released into the bloodstream following cardiac muscle injury or stress, including troponin, creatine kinase-MB, B-type natriuretic peptide, and myoglobin. These devices are central to the rapid diagnosis and risk stratification of acute coronary syndrome, myocardial infarction, and congestive heart failure in both centralized laboratory and decentralized point-of-care environments. The market is organized by product type across instruments and reagents & kits; by biomarker type, including troponin, creatine kinase-MB, B-type natriuretic peptide, myoglobin, and other emerging markers; by testing setting across laboratory testing and point-of-care testing; by application, led by acute coronary syndrome, congestive heart failure, and myocardial infarction; and by end-user, spanning hospitals, pathology laboratories, and other care settings. Driven by the rising global prevalence of cardiovascular disease, the shift toward high-sensitivity and rapid-turnaround assays, and the expansion of point-of-care testing in emergency departments and ambulatory settings, cardiac biomarkers testing devices have become an indispensable component of modern cardiovascular diagnostic pathways.

Cardiac Biomarkers Testing Devices Market Key Growth Drivers

• The rising global burden of cardiovascular disease, including acute coronary syndrome, myocardial infarction, and heart failure, is driving sustained demand for rapid and accurate cardiac biomarker testing across hospitals and diagnostic laboratories worldwide.
• The growing adoption of high-sensitivity troponin assays, which detect smaller elevations in troponin and allow earlier rule-in and rule-out of myocardial infarction, is expanding demand for compatible instruments and reagents.
• Rapid growth in point-of-care testing, driven by the need for faster turnaround in emergency departments, ambulances, and outpatient clinics, is broadening the installed base of portable cardiac biomarker analyzers.
• The rising geriatric population and the increasing prevalence of risk factors such as hypertension, diabetes, and obesity are expanding the pool of patients requiring cardiac biomarker evaluation.
• Continuous technological advancement, including multiplex cardiac panels, automated chemiluminescence platforms, and improved lateral-flow immunoassays, is improving diagnostic accuracy and expanding testing menus.
• Growing government and private healthcare investment in cardiovascular disease screening and emergency care infrastructure, particularly across emerging economies, is expanding access to cardiac biomarker testing.
• Strategic product launches, regulatory clearances, and partnerships among leading diagnostics manufacturers are expanding testing menus and geographic reach, sustaining competitive intensity and market growth through 2034.

Key Companies in Cardiac Biomarkers Testing Devices Market

The competitive landscape is led by the following active manufacturers:

• Beckman Coulter, Inc.
• Siemens Healthcare GmbH
• Abbott
• bioMerieux SA
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Eurolyser Diagnostica GmbH
• Diagnostic Automation / Cortez Diagnostics, Inc.
• Randox Laboratories Ltd.

Factors Contributing to the Growth of the Cardiac Biomarkers Testing Devices Market

Market Drivers

Rising Global Burden of Cardiovascular Disease

The most powerful driver of the Cardiac Biomarkers Testing Devices market is the rising global burden of cardiovascular disease, which remains the leading cause of death worldwide. Acute coronary syndrome, myocardial infarction, and congestive heart failure require rapid, accurate biochemical confirmation, and cardiac biomarker testing is central to emergency triage, diagnosis, and ongoing disease management. As the incidence of coronary artery disease and heart failure continues to climb, particularly in aging and increasingly sedentary populations, hospitals and diagnostic laboratories are expanding testing volumes and capacity. This sustained clinical need anchors durable, recurring demand for both instruments and reagents & kits across the forecast period.

Growing Adoption of High-Sensitivity Troponin Assays

The shift toward high-sensitivity troponin assays is a central growth engine for the market. High-sensitivity tests detect much smaller elevations of cardiac troponin than earlier-generation assays, enabling clinicians to rule in or rule out myocardial infarction within one to three hours of presentation rather than waiting for serial testing over several hours. This accelerates emergency department decision-making, reduces length of stay, and improves diagnostic accuracy, particularly in women and patients with atypical presentations. As clinical guidelines increasingly recommend high-sensitivity troponin as the standard of care, adoption of compatible analyzers and reagents continues to expand across hospital and reference laboratories.

Market Restraints

Despite strong momentum, the Cardiac Biomarkers Testing Devices market faces material constraints. The high cost of advanced analyzers and high-sensitivity assay reagents limits adoption in cost-constrained healthcare systems and smaller laboratories, particularly across low- and middle-income countries. Reimbursement policies for cardiac biomarker testing vary considerably across geographies, and inconsistent coverage can slow adoption of newer, higher-cost assays. Stringent regulatory requirements for diagnostic clearance and quality assurance lengthen product development timelines and raise compliance costs for manufacturers. A shortage of trained laboratory personnel in emerging markets constrains testing capacity, while the proliferation of point-of-care devices raises quality-control and standardization challenges relative to centralized laboratory testing. Additionally, growing competitive pressure and periodic pricing pressure on established biomarker assays can compress margins for manufacturers. Together, these cost, reimbursement, regulatory, workforce, and standardization barriers temper the pace of growth, even as the underlying drivers of rising cardiovascular disease burden and testing innovation remain firmly intact.

Cardiac Biomarkers Testing Devices Market Segment Analysis

The Cardiac Biomarkers Testing Devices Market is segmented by product type (instruments, reagents & kits), biomarker type (troponin, creatine kinase-MB, B-type natriuretic peptide, myoglobin, others), testing settings (laboratory testing, point-of-care testing), application (acute coronary syndrome, congestive heart failure, myocardial infarction, others), end-user (hospitals, pathology labs, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Reagents & Kits.

The reagents & kits segment accounted for 64% of the Cardiac Biomarkers Testing Devices market in 2025. Reagents and kits lead the product type category because every cardiac biomarker test, whether performed in a central laboratory or at the point of care, consumes assay-specific reagents on a recurring, per-test basis, generating steady repeat revenue that scales directly with testing volume. The broad installed base of laboratory analyzers and point-of-care devices across hospitals and diagnostic laboratories continually drives reagent and kit consumption, and manufacturers benefit from stable, annuity-like revenue streams tied to consumables rather than one-time capital equipment sales. While instruments are growing quickly on the back of new high-sensitivity and multiplex analyzer launches, the sheer volume and recurring nature of reagent and kit consumption secure the segment's leadership across the forecast period.

By Biomarker Type

Dominant Subsegment: Troponin.

The troponin segment accounted for 43% of the Cardiac Biomarkers Testing Devices market in 2025. Troponin is the leading biomarker type because cardiac troponin I and T are the most sensitive and specific markers of myocardial injury, forming the cornerstone of clinical guidelines for diagnosing acute myocardial infarction and acute coronary syndrome. The ongoing shift toward high-sensitivity troponin assays, which detect smaller elevations and support earlier rule-in and rule-out protocols in the emergency department, continues to reinforce demand across both laboratory and point-of-care settings. While B-type natriuretic peptide is growing rapidly on the back of expanding heart failure diagnosis and monitoring, the breadth of clinical use, guideline endorsement, and testing frequency associated with troponin secure its leadership across the forecast period.

Cardiac Biomarkers Testing Devices Market Region Analysis

Dominant Region: North America

North America accounted for 39% of the global Cardiac Biomarkers Testing Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature cardiovascular care infrastructure, high awareness and early adoption of high-sensitivity troponin testing, well-established reimbursement pathways, and the concentrated presence of leading diagnostics manufacturers headquartered in the United States. North America hosts a dense network of hospitals and reference laboratories equipped with advanced automated immunoassay platforms, and emergency departments across the region have widely adopted rapid rule-in and rule-out troponin protocols. Continued investment in point-of-care testing infrastructure, combined with a high prevalence of cardiovascular risk factors and an aging population, sustains substantial testing volumes and anchors the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Cardiac Biomarkers Testing Devices market. The region's elevated CAGR is driven by the rising incidence of cardiovascular disease, rapid expansion of hospital and diagnostic laboratory infrastructure, and growing healthcare investment across China, India, Japan, and South Korea. China and India are expanding emergency and cardiac care capacity in both urban and rural settings, Japan continues to adopt next-generation high-sensitivity assays, and South Korea is investing in advanced automated laboratory platforms. Rising awareness of early cardiac diagnosis, expanding health insurance coverage, and growing local manufacturing of point-of-care devices are accelerating adoption across the region, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 39% of the global Cardiac Biomarkers Testing Devices market revenue in 2025. The United States dominates the region on the strength of its advanced cardiovascular care infrastructure, widespread adoption of high-sensitivity troponin testing, favorable reimbursement environment, and the presence of leading diagnostics manufacturers, while Canada contributes steady growth through expanding public hospital laboratory capacity.

Europe

Europe is a large and technologically advanced regional market, supported by established CE-IVDR regulatory frameworks, strong national healthcare systems, and widespread adoption of automated immunoassay platforms across Germany, France, the United Kingdom, Italy, and Spain. Rising cardiovascular disease prevalence and growing investment in point-of-care testing across emergency medical services are reinforcing steady regional growth.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, rapid hospital and laboratory infrastructure build-out, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Expanding insurance coverage, rising awareness of early cardiac diagnosis, and increasing local manufacturing capacity are accelerating regional adoption of both laboratory and point-of-care cardiac biomarker testing devices.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital and emergency care infrastructure, rising cardiovascular disease burden, and gradual improvements in diagnostic laboratory capacity are broadening access to cardiac biomarker testing, while international partnerships and donor-supported healthcare programs support the build-out of regional testing capacity.

Cardiac Biomarkers Testing Devices Market Competitive Landscape

The Cardiac Biomarkers Testing Devices market is classified as Consolidated. A group of large, diversified in-vitro diagnostics companies with broad automated immunoassay platforms, including Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, and Beckman Coulter, Inc., secures the majority of hospital and reference laboratory contracts and anchors the top tier, while specialized providers such as bioMerieux SA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc., and Randox Laboratories Ltd. compete through focused biomarker panels, point-of-care platforms, and quality-control offerings, sustaining competitive intensity across both laboratory and decentralized testing settings.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Consolidated, with large diversified in-vitro diagnostics leaders anchoring the top tier alongside specialized point-of-care and niche assay providers.
• Leading players: Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, and Beckman Coulter, Inc. anchor the top tier through broad automated immunoassay platforms and global laboratory installed bases.
• Geographic reach: Leading players operate global distribution and service networks spanning hospitals, reference laboratories, and point-of-care settings across all major regions.
• Product portfolio strength: Top players offer end-to-end cardiac biomarker portfolios spanning high-sensitivity troponin, natriuretic peptide, and multiplex panels across both laboratory and point-of-care formats.
• Technology depth: Ownership of proprietary immunoassay chemistries, automated analyzer platforms, and biochip array technology is a decisive competitive advantage.
• Strategic partnerships: Distribution agreements, co-marketing partnerships, and collaborations with hospital networks extend market reach and accelerate adoption of new assays.
• M&A and portfolio activity: Ongoing acquisitions and portfolio expansions among diagnostics majors continue to consolidate biomarker testing capabilities and broaden geographic coverage.
• Manufacturing capabilities: Automated, high-throughput reagent and kit manufacturing combined with quality-control expertise are key competitive moats.
• Innovation focus: Next-generation high-sensitivity troponin assays, multiplex cardiac panels, compact point-of-care analyzers, and digital connectivity for result reporting.

Cardiac Biomarkers Testing Devices Market Recent Developmental Activities

In 2025-2026, Beckman Coulter, Inc., expanded its high-sensitivity troponin I assay menu on its automated immunoassay analyzer platforms to support faster rule-in and rule-out protocols in emergency care. Strategic significance: Strengthens laboratory testing portfolio and reinforces Beckman Coulter's position among leading automated immunoassay providers.

In 2025-2026, Siemens Healthcare GmbH advanced its Atellica-based cardiac assay menu with additional high-sensitivity troponin and natriuretic peptide tests to support integrated cardiac risk assessment. Strategic significance: Expands cardiac testing depth on a widely installed automated laboratory platform.

Cardiac Biomarkers Testing Devices Market Segmentation

Cardiac Biomarkers Testing Devices Market by Product Type

• Instruments
• Reagents & Kits

Cardiac Biomarkers Testing Devices Market by Biomarker Type

• Troponin
• Creatine Kinase-MB
• B-Type Natriuretic Peptide
• Myoglobin
• Others

Cardiac Biomarkers Testing Devices Market by Testing Settings

• Laboratory Testing
• Point-of-Care Testing

Cardiac Biomarkers Testing Devices Market by Application

• Acute Coronary Syndrome
• Congestive Heart Failure
• Myocardial Infarction
• Others

Cardiac Biomarkers Testing Devices Market by End-User

• Hospitals
• Pathology Labs
• Others

Cardiac Biomarkers Testing Devices Market by Geography

• North America Cardiac Biomarkers Testing Devices Market
• United States Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Canada Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Mexico Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Europe Cardiac Biomarkers Testing Devices Market
• Germany Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• United Kingdom Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• France Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Italy Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Spain Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Rest of Europe Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Asia-Pacific Cardiac Biomarkers Testing Devices Market
• China Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Japan Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• India Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Australia Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• South Korea Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) Cardiac Biomarkers Testing Devices Market
• Middle East Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• Africa Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)
• South America Cardiac Biomarkers Testing Devices Market Size in USD million (2023-2034)

Key Takeaways from the Cardiac Biomarkers Testing Devices Market Report Study

• Market size analysis for the current Cardiac Biomarkers Testing Devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global Cardiac Biomarkers Testing Devices market.
• Various opportunities available for competitors in the Cardiac Biomarkers Testing Devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Cardiac Biomarkers Testing Devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Cardiac Biomarkers Testing Devices market growth in the future?

Target audience who can benefit from this Cardiac Biomarkers Testing Devices market report study

• Cardiac Biomarkers Testing Devices product providers
• Research organizations and consulting companies
• Cardiac Biomarkers Testing Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Cardiac Biomarkers Testing Devices
• Various end-users who want to know more about the Cardiac Biomarkers Testing Devices market and the latest technological developments in the Cardiac Biomarkers Testing Devices market.

Frequently Asked Questions:

Q1. What is the growth rate of the Cardiac Biomarkers Testing Devices market?

The Cardiac Biomarkers Testing Devices market is projected to expand at a CAGR of 9.4% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Cardiac Biomarkers Testing Devices market?

The Cardiac Biomarkers Testing Devices market is estimated at USD 5.24 billion in 2025 and is projected to reach USD 11.77 billion by 2034.

Q3. Which region dominates the Cardiac Biomarkers Testing Devices market?

North America dominated the Cardiac Biomarkers Testing Devices market with a 39% share of global revenue in 2025, supported by a mature cardiovascular care infrastructure, widespread adoption of high-sensitivity troponin testing, favorable reimbursement pathways, and the concentrated presence of leading diagnostics manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Cardiac Biomarkers Testing Devices market?

The principal drivers are the rising global burden of cardiovascular disease; the growing adoption of high-sensitivity troponin assays that enable earlier and more accurate diagnosis of myocardial infarction; the rapid expansion of point-of-care cardiac testing in emergency and ambulatory care settings; the rising geriatric population and increasing prevalence of cardiovascular risk factors; and continuous technological advancement in immunoassay and analyzer platforms.

Q5. Who are the major players in the Cardiac Biomarkers Testing Devices market?

The major players include Beckman Coulter, Inc., Siemens Healthcare GmbH, Abbott, bioMerieux SA, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc., and Randox Laboratories Ltd., among other active providers profiled in the Competitive Landscape section. Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, and Beckman Coulter, Inc. lead through broad automated immunoassay platforms and global laboratory installed bases.